Top 1% Biotech Yo-Yos, But Hits A Record, On NASH Enthusiasm

unveiled promising test results Tuesday for a liver disease treatment, and VKTX stock hit a record high after initially yo-yoing on the news. The company is working on a treatment for nonalcoholic steatohepatitis, or NASH. With NASH, patients experience inflammation and damage in the liver…#nash #insightpartners #vk2809 #brianlian #marketsmithcom #ibddigital #elililly #trackandbuy
Source: Reuters: Health - Category: Consumer Health News Source Type: news